Evidence map›Paper›PMID 38419881›Full record

ArticleNanoscale advances2024

Charge neutralized poly(β-amino ester) polyplex nanoparticles for delivery of self-amplifying RNA.

Nazgol Karimi Dastgerdi, Nurcan Gumus, Hulya Bayraktutan, Darryl Jackson, Krunal Polra, Paul F McKay, Fatemeh Atyabi, Rassoul Dinarvand, Robin J Shattock, Luisa Martinez-Pomares and 2 more

Open access · goldAbstract read
In one paragraph

Article in Nanoscale advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Nazgol Karimi DastgerdiDivision of Molecular Therapeutics and Formulation, School of Pharmacy, University of Nottingham NG7 2RD UK cameron.alexander@nottingham.ac.uk.ORCID https://orcid.org/0009-0008-8996-0484
Nurcan GumusDivision of Molecular Therapeutics and Formulation, School of Pharmacy, University of Nottingham NG7 2RD UK cameron.alexander@nottingham.ac.uk.
Hulya BayraktutanDivision of Molecular Therapeutics and Formulation, School of Pharmacy, University of Nottingham NG7 2RD UK cameron.alexander@nottingham.ac.uk.
Darryl JacksonSchool of Life Sciences, Faculty of Medicine & Health Sciences, University of Nottingham NG7 2RD UK.
Krunal PolraDepartment of Infectious Diseases, Section of Immunology of Infection, Imperial College London Norfolk Place London W21PG UK.
Paul F McKayDepartment of Infectious Diseases, Section of Immunology of Infection, Imperial College London Norfolk Place London W21PG UK.
Fatemeh AtyabiDepartment of Pharmaceutical Nanotechnology, School of Pharmacy, Tehran University of Medical Sciences Tehran Iran.
Rassoul DinarvandDepartment of Pharmaceutical Nanotechnology, School of Pharmacy, Tehran University of Medical Sciences Tehran Iran.ORCID https://orcid.org/0000-0003-0694-7556
Robin J ShattockDepartment of Infectious Diseases, Section of Immunology of Infection, Imperial College London Norfolk Place London W21PG UK.
Luisa Martinez-PomaresSchool of Life Sciences, Faculty of Medicine & Health Sciences, University of Nottingham NG7 2RD UK.ORCID https://orcid.org/0000-0002-2331-127X
Pratik GurnaniUCL School of Pharmacy, University College London 29-39 Brunswick Square London WC1N 1AX UK p.gurnani@ucl.ac.uk.ORCID https://orcid.org/0000-0002-6559-5514
Cameron AlexanderDivision of Molecular Therapeutics and Formulation, School of Pharmacy, University of Nottingham NG7 2RD UK cameron.alexander@nottingham.ac.uk.ORCID https://orcid.org/0000-0001-8337-1875
University of Nottingham · GBImperial College London · GBTehran University of Medical Sciences · IRUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic self-amplifying RNA (saRNA) is a promising approach for disease treatment, as it can be administered in lower doses than messenger RNA (mRNA) to achieve comparable protein production levels. However, saRNA requires an appropriate delivery vehicle to protect it during transit and facilitate its transfection. A widely-adopted approach has been to use polycations to condense these large anionic macromolecules into polyplex nanoparticles, however their high charge density often elicits cytotoxic effects. In this study we postulated that we could improve the potency and tolerability of such delivery vehicles by co-formulating poly(β-amino ester)s saRNA polyplexes with a non-toxic anionic polymer, γ-polyglutamic acid (γ-PGA) to neutralize partially this positive charge. Accordingly, we prepared a poly(β-amino ester) from 1,6-hexanedioldiacrylate (HDDA) and 4-aminobutanol (ABOL) and initially evaluated the physicochemical properties of the binary polyplexes (

Identifiers

PMID38419881
PMCPMC10898429
OpenAlexW4391176976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.